Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Amber Salter

Showing results (1-10 of 232) with videos related to

Pageof 24
Sort By:
Neurology|September 2, 2021
Assessment of Biological Interactions Between Multiple Sclerosis Status and Depression for MortalityAmber Salter
Annals of Neurology|July 26, 2011
Got milk?Gary Cutter, Amber Salter
Neurology|July 1, 2021
Differing Impact of Disease-Modifying Therapy on Relapse and Progression: Time to Consider Inflammation and Neuroprotection Separately?Ruth Dobson, Amber Salter
Neurology|September 8, 2023
Using a Bayesian Reanalysis Approach to Evaluate the Probability of Benefit From the MISTIE InterventionAmber Salter, Wesley T Kerr
Neurology|January 22, 2020
Dual antiplatelets in IV thrombolysis: How much is too much?Vasileios-Arsenios Lioutas, Amber Salter
Neurology|February 26, 2024
Off-Road Testing: Outcome Reporting Bias in Multiple Sclerosis TrialsRuth Ann Marrie, Amber Salter
International Journal of MS Care|January 17, 2022
Guest EditorialRuth Ann Marrie, Amber Salter
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 27, 2023
Assessing everyday functional activity in cognitively impaired people with multiple sclerosis: The use of Actual Reality<sup>TM</sup>Yael Goverover, Amber Salter, John DeLuca
Computer Methods and Programs in Biomedicine|July 1, 2015
Implementation of a two-group likelihood time-to-event continual reassessment method using SASAmber Salter, Charity Morgan, Inmaculada B Aban
Multiple Sclerosis Journal - Experimental, Translational and Clinical|March 11, 2017
Efficacy and tolerability of oral versus injectable disease-modifying therapies for multiple sclerosis in clinical practiceErin E Longbrake, Anne H Cross, Amber Salter
Pageof 24

Showing results (1-10 of 232) with videos related to

Sort By:
Pageof 24
Neurology|September 2, 2021
Assessment of Biological Interactions Between Multiple Sclerosis Status and Depression for MortalityAmber Salter
Annals of Neurology|July 26, 2011
Got milk?Gary Cutter, Amber Salter
Neurology|July 1, 2021
Differing Impact of Disease-Modifying Therapy on Relapse and Progression: Time to Consider Inflammation and Neuroprotection Separately?Ruth Dobson, Amber Salter
Neurology|September 8, 2023
Using a Bayesian Reanalysis Approach to Evaluate the Probability of Benefit From the MISTIE InterventionAmber Salter, Wesley T Kerr
Neurology|January 22, 2020
Dual antiplatelets in IV thrombolysis: How much is too much?Vasileios-Arsenios Lioutas, Amber Salter
Neurology|February 26, 2024
Off-Road Testing: Outcome Reporting Bias in Multiple Sclerosis TrialsRuth Ann Marrie, Amber Salter
International Journal of MS Care|January 17, 2022
Guest EditorialRuth Ann Marrie, Amber Salter
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 27, 2023
Assessing everyday functional activity in cognitively impaired people with multiple sclerosis: The use of Actual Reality<sup>TM</sup>Yael Goverover, Amber Salter, John DeLuca
Computer Methods and Programs in Biomedicine|July 1, 2015
Implementation of a two-group likelihood time-to-event continual reassessment method using SASAmber Salter, Charity Morgan, Inmaculada B Aban
Multiple Sclerosis Journal - Experimental, Translational and Clinical|March 11, 2017
Efficacy and tolerability of oral versus injectable disease-modifying therapies for multiple sclerosis in clinical practiceErin E Longbrake, Anne H Cross, Amber Salter
Pageof 24